Trade Lyell Immunopharma, Inc. - LYEL CFD

Add to favourite

2.21

4.33%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.05

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Lyell Immunopharma Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	2.31
Open*	2.26
1-Year Change*	-4.24%
Day's Range*	2.13 - 2.35
52 wk Range	1.32-3.97
Average Volume (10 days)	1.48M
Average Volume (3 months)	27.27M
Market Cap	496.18M
P/E Ratio	-100.00K
Shares Outstanding	251.87M
Revenue	48.50M
EPS	-0.76
Dividend (Yield %)	N/A
Beta	-100.00K
Next Earnings Date	N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	2.31	0.01	0.43%	2.30	2.39	2.23
Apr 17, 2024	2.37	-0.01	-0.42%	2.38	2.46	2.33
Apr 16, 2024	2.38	0.13	5.78%	2.25	2.47	2.24
Apr 15, 2024	2.37	-0.41	-14.75%	2.78	2.81	2.33
Apr 12, 2024	2.99	0.10	3.46%	2.89	3.12	2.79
Apr 11, 2024	2.64	0.21	8.64%	2.43	2.64	2.43
Apr 10, 2024	2.42	-0.01	-0.41%	2.43	2.43	2.29
Apr 9, 2024	2.49	0.32	14.75%	2.17	2.60	2.17
Apr 8, 2024	2.18	0.10	4.81%	2.08	2.19	2.04
Apr 5, 2024	2.07	0.06	2.99%	2.01	2.11	1.98
Apr 4, 2024	2.08	0.06	2.97%	2.02	2.18	2.02
Apr 3, 2024	2.04	0.07	3.55%	1.97	2.07	1.96
Apr 2, 2024	2.05	-0.03	-1.44%	2.08	2.10	2.02
Apr 1, 2024	2.16	-0.07	-3.14%	2.23	2.25	2.04
Mar 28, 2024	2.22	0.21	10.45%	2.01	2.23	1.99
Mar 27, 2024	2.01	0.10	5.24%	1.91	2.02	1.91
Mar 26, 2024	1.91	0.01	0.53%	1.90	1.96	1.88
Mar 25, 2024	1.90	0.04	2.15%	1.86	1.93	1.86
Mar 22, 2024	1.90	-0.08	-4.04%	1.98	2.01	1.89
Mar 21, 2024	2.01	0.03	1.52%	1.98	2.07	1.93

Lyell Immunopharma, Inc. Events

Time (UTC)	Country	Event
No events scheduled

View all events

Annual
Quarterly

	2022	2021	2020	2019
Total revenue	84.683	10.65	7.756	0.657
Revenue	84.683	10.65	7.756	0.657
Total Operating Expense	276.741	261.873	219.693	102.746
Selling/General/Admin. Expenses, Total	117.307	89.057	46.881	39.151
Research & Development	164.318	134.98	182.243	63.595
Other Operating Expenses, Total	-9.884	1.089	-9.431	0
Operating Income	-192.058	-251.223	-211.937	-102.089
Interest Income (Expense), Net Non-Operating	5.986	0.909	5.939	8.121
Other, Net	2.954	0.095	1.526	-35.409
Net Income Before Taxes	-183.118	-250.219	-204.472	-129.377
Net Income After Taxes	-183.118	-250.219	-204.472	-129.377
Net Income Before Extra. Items	-183.118	-250.219	-204.472	-129.377
Net Income	-183.118	-250.219	-204.472	-129.377
Income Available to Common Excl. Extra. Items	-183.118	-250.219	-204.472	-129.377
Income Available to Common Incl. Extra. Items	-183.118	-250.219	-204.472	-129.377
Diluted Net Income	-183.118	-250.219	-204.472	-129.377
Diluted Weighted Average Shares	249.567	242.738	242.83	242.83
Diluted EPS Excluding Extraordinary Items	-0.73374	-1.03082	-0.84204	-0.53279
Dividends per Share - Common Stock Primary Issue			0	0
Diluted Normalized EPS	-0.71371	-0.87943	-0.84204	-0.53279
Unusual Expense (Income)	5	36.747

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0.027	0.065	48.386	0.003	35.741
Revenue	0.027	0.065	48.386	0.003	35.741
Total Operating Expense	68.855	72.621	63.17	71.44	73.002
Selling/General/Admin. Expenses, Total	19.03	19.279	26.348	26.084	30.454
Research & Development	47.471	46.338	45.339	39.166	40.132
Other Operating Expenses, Total	-0.569	-2.996	-8.517	1.19	2.416
Operating Income	-68.828	-72.556	-14.784	-71.437	-37.261
Interest Income (Expense), Net Non-Operating	5.264	4.497	3.453	1.17	0.938
Other, Net	-0.326	1.1	2.934	0.013
Net Income Before Taxes	-63.89	-66.959	-8.397	-70.254	-36.323
Net Income After Taxes	-63.89	-66.959	-8.397	-70.254	-36.323
Net Income Before Extra. Items	-63.89	-66.959	-8.397	-70.254	-36.323
Net Income	-63.89	-66.959	-8.397	-70.254	-36.323
Income Available to Common Excl. Extra. Items	-63.89	-66.959	-8.397	-70.254	-36.323
Income Available to Common Incl. Extra. Items	-63.89	-66.959	-8.397	-70.254	-36.323
Diluted Net Income	-63.89	-66.959	-8.397	-70.254	-36.323
Diluted Weighted Average Shares	250.204	249.591	259.414	248.32	246.312
Diluted EPS Excluding Extraordinary Items	-0.25535	-0.26827	-0.03237	-0.28292	-0.14747
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.24367	-0.22821	-0.03237	-0.26278	-0.14747
Unusual Expense (Income)	2.923	10	0	5

Annual
Quarterly

	2022	2021	2020	2019
Total Current Assets	651.295	626.286	617.547	440.259
Cash and Short Term Investments	640.152	614.794	612.619	436.049
Cash & Equivalents	123.554	293.828	140.406	96.674
Short Term Investments	516.598	320.966	472.213	339.375
Prepaid Expenses	11.143	11.492	4.928	4.21
Total Assets	937.561	1127.41	908.28	555.631
Property/Plant/Equipment, Total - Net	166.265	166.639	124.055	43.705
Property/Plant/Equipment, Total - Gross	198.649	181.152	129.159	44.961
Accumulated Depreciation, Total	-32.384	-14.513	-5.104	-1.256
Long Term Investments	115.041	330.532	163.443	68.983
Other Long Term Assets, Total	4.96	3.949	3.235	2.684
Total Current Liabilities	37.028	46.738	49.285	22.045
Accounts Payable	3.917	3.207	9.396	2.844
Accrued Expenses	26.403	27.588	26.952	13.019
Notes Payable/Short Term Debt	0	0	0	0
Other Current Liabilities, Total	6.708	15.943	12.937	6.182
Total Liabilities	104.309	197.619	189.84	147.576
Total Long Term Debt	0	0	0	0
Other Liabilities, Total	67.281	150.881	140.555	125.531
Total Equity	833.252	929.787	718.44	408.055
Redeemable Preferred Stock	0	0	1010.97	519.163
Common Stock	0.025	0.024	0.002	0.001
Additional Paid-In Capital	1608.31	1515.75	41.357	18.108
Retained Earnings (Accumulated Deficit)	-767.48	-584.362	-334.143	-129.671
Other Equity, Total	-7.599	-1.623	0.256	0.454
Total Liabilities & Shareholders’ Equity	937.561	1127.41	908.28	555.631
Total Common Shares Outstanding	249.567	242.738	242.83	242.83

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	586.854	606.41	624.398	651.295	659.745
Cash and Short Term Investments	575.431	595.748	612.769	640.152	648.132
Cash & Equivalents	286.214	224.372	109.426	123.554	116.311
Short Term Investments	289.217	371.376	503.343	516.598	531.821
Prepaid Expenses	11.423	10.662	11.629	11.143	11.613
Total Assets	794.989	835.354	880.45	937.561	977.269
Property/Plant/Equipment, Total - Net	148.699	155.189	160.99	166.265	169.811
Long Term Investments	54.73	68.953	90.179	115.041	144.52
Other Long Term Assets, Total	4.706	4.802	4.883	4.96	3.193
Total Current Liabilities	35.064	34.39	30.797	37.028	51.217
Accounts Payable	4.365	5.805	5.733	3.917	4.795
Accrued Expenses	29.652	24.832	22.416	28.755	23.568
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	1.047	3.753	2.648	4.356	22.854
Total Liabilities	97.416	98.499	96.624	104.309	157.243
Total Long Term Debt	0	0	0	0	0
Other Liabilities, Total	62.352	64.109	65.827	67.281	106.026
Total Equity	697.573	736.855	783.826	833.252	820.026
Redeemable Preferred Stock			0	0	0
Common Stock	0.025	0.025	0.025	0.025	0.025
Additional Paid-In Capital	1647.91	1637.54	1622.12	1608.31	1589.08
Retained Earnings (Accumulated Deficit)	-949.182	-898.329	-834.439	-767.48	-759.083
Other Equity, Total	-1.181	-2.379	-3.879	-7.599	-9.996
Total Liabilities & Shareholders’ Equity	794.989	835.354	880.45	937.561	977.269
Total Common Shares Outstanding	251.869	251.027	249.609	249.567	249.24

Annual
Quarterly

	2022	2021	2020	2019
Net income/Starting Line	-183.118	-250.219	-204.472	-129.377
Cash From Operating Activities	-169.555	-126.249	-160.874	39.474
Cash From Operating Activities	18.02	13.624	4.294	1.256
Non-Cash Items	77.558	106.331	39.64	56.787
Changes in Working Capital	-82.015	4.015	-0.336	110.808
Cash From Investing Activities	-11.54	-121.573	-273.516	-422.433
Capital Expenditures	-24.276	-65.504	-51.481	-16.047
Other Investing Cash Flow Items, Total	12.736	-56.069	-222.035	-406.386
Cash From Financing Activities	10.635	401.244	476.79	351.156
Issuance (Retirement) of Stock, Net	11.096	401.244	476.79	351.156
Net Change in Cash	-170.46	153.422	42.4	-31.803
Financing Cash Flow Items	-0.461

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-66.959	-183.118	-174.721	-104.467	-68.144
Cash From Operating Activities	-46.212	-169.555	-129.288	-92.185	-47.852
Cash From Operating Activities	5.027	18.02	12.979	8.358	4.187
Non-Cash Items	20.031	77.558	71.076	44.295	18.494
Changes in Working Capital	-4.311	-82.015	-38.622	-40.371	-2.389
Cash From Investing Activities	32.154	-11.54	-58.188	-1.103	-26.122
Capital Expenditures	-1.533	-24.276	-19.694	-16.903	-9.733
Other Investing Cash Flow Items, Total	33.687	12.736	-38.494	15.8	-16.389
Cash From Financing Activities	-0.069	10.635	9.772	5.012	2.555
Issuance (Retirement) of Stock, Net	0	11.096	10.139	5.012	2.555
Net Change in Cash	-14.127	-170.46	-177.704	-88.276	-71.419
Financing Cash Flow Items	-0.069	-0.461	-0.367

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Lyell Immunopharma, Inc. Company profile

About Lyell Immunopharma Inc

Lyell Immunopharma, Inc is a T cell reprogramming company. The Company offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. It builds a multi-modality product pipeline across solid tumor indications with unmet needs and anticipate having investigational new drug application (IND). It offers Gen-R and Epi-R technology platforms. Its Gen-R is its ex vivo genetic reprogramming technology to overcome T cell exhaustion. Its Epi-R is an ex vivo epigenetic reprogramming technology to create a population of T cells with durable stemness. Epi-R is designed to generate populations of T cells which have this property of durable stemness. It utilizes its Gen-R and Epi-R technology platforms to develop a multi-modality product pipeline.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Lyell Immunopharma Inc revenues increased 44% to $7.8M. Net loss increased 1% to $166.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $11.3M to $28.4M (expense), General and administrative - Balanc increase of 39% to $28.8M (expense).

Industry:

Bio Therapeutic Drugs

201 Haskins Way
Suite 301
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024